Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures
This study examined differences between men and women in factors affecting anti-osteoporosis drug treatment after osteoporotic fracture. Using a national claims database, we analyzed patients aged 50 years and older who experienced their first osteoporotic fracture between January 1, 2008, and December 31, 2012. We examined whether patients were prescribed anti-osteoporosis drugs within 6 months post-fracture. Factors associated with treatment status were identified using multivariate logistic regression. Among a total of 556,410 patients aged 50 and older, only 37% were prescribed anti-osteoporosis drugs within 6 months post-fracture. Female patients with fractures were more likely to receive pharmacotherapy than male patients (41.7 vs. 19.3%). Older age significantly increased the likelihood of receiving anti-osteoporosis drugs after osteoporotic fracture. For men, the adjusted odds ratio for receiving therapy was greatest in those aged 80 years and older (OR 6.4), and for women, it was largest in those aged 70–79 (OR 3.33). Both men and women were more likely to be prescribed drugs after a spine fracture, with men having significantly greater odds of receiving drug therapy (men, OR 7.1, 95% CI 6.5–7.9; women 4.79, CI 4.63–4.96). Patients with rheumatic disease or other osteoporosis-inducing comorbid disease were more likely to be prescribed anti-osteoporosis drugs. Our findings indicate that a lack of anti-osteoporosis pharmacotherapy after fracture remains a problem in Korea, especially among men, highlighting the need for effective quality improvement interventions to maximize post-fracture treatment rates.
KeywordsFractures Gender differences Pharmacotherapy Post-fracture treatment Osteoporosis
The National Health Insurance Database was made available by the National Health Insurance Service (NHIS) of Korea (NHIS-2017-4-054). The authors would like to thank the NHIS for its cooperation. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Korea (grant number HI13C1522).
Compliance with ethical standards
Conflict of Interest
All authors have no conflicts of interest.
- 6.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382. https://doi.org/10.1016/j.bone.2004.03.024 CrossRefGoogle Scholar
- 15.Kim HY, Jang EJ, Park B, Kim TY, Shin SA, Ha YC, Jang S (2016) Development of a Korean Fracture Risk Score (KFRS) for predicting osteoporotic fracture risk: analysis of data from the Korean National Health Insurance Service. PLoS One 11:e0158918. https://doi.org/10.1371/journal.pone.0158918 CrossRefGoogle Scholar
- 16.Skedros JG, Holyoak JD, Pitts TC (2006) Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture. J Bone Joint Surg Am 88:18–24Google Scholar
- 17.Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326Google Scholar
- 19.Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. In: Mayo Clinic Proceedings. Elsevier, vol 2, p 194–202Google Scholar
- 20.Jaglal SB, Carroll J, Hawker G, McIsaac WJ, Jaakkimainen L, Cadarette SM, Cameron C, Davis D (2003) How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can Fam Physician 49:462–468Google Scholar
- 27.Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, Brown JP, Hanley DA, Murray TM (2004) Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol 31:1993–1995Google Scholar